Sun Piaoyang, Chairperson, Jiangsu Hengrui Pharmaceuticals
The global pharmaceutical manufacturing industry is undergoing a profound transformation, driven by rapid scientific advancements, stringent regulatory frameworks, and increasing demand for high-quality, accessible healthcare solutions.
Companies are intensifying their focus on research and development, precision medicine, and complex generics to address evolving clinical needs across diverse therapeutic areas.
At the same time, the industry is witnessing a shift toward innovation-led growth, with investments in biotechnology, digital integration, and advanced manufacturing processes enhancing efficiency and scalability.
As healthcare challenges become more complex, pharmaceutical manufacturers are playing a critical role in shaping a resilient, future-ready ecosystem focused on improving patient outcomes and extending quality of life.
One such company that operates as an international pharmaceutical company and develops and markets high-quality medical products to solve clinical problems that have not been resolved yet is Jiangsu Hengrui Pharmaceuticals.
The Jiangsu Hengrui Pharmaceuticals also known as Hengrui Pharma develops treatments for six medical fields which include cancer, metabolic disorders, cardiovascular diseases, immunological, respiratory diseases, and neuroscience.
Hengrui Pharma started its operations in 1970 by establishing a patient-centric business model which continues to guide its mission to develop scientific solutions that prevent diseases and improve human health and lifespan.
A Leading Force in the Pharmaceutical Sector
Hengrui has maintained scientific and technological innovation as its main development strategy while increasing its research and development funding. Hengrui has invested over RMB 50 billion in research and development which establishes the company as the leading force in China's pharmaceutical sector.
The company has established 15 research and development centers throughout the world which include locations in Asia, Europe and the United States and Australia. Its research and development expenditures result in successful product innovations.
Innovation in pharmaceuticals is no longer optional, it is essential to addressing the growing complexity of global healthcare and improving patient outcomes worldwide
The company has introduced to the market 24 new molecular entity drugs and 5 additional innovative drugs in China. It currently possesses more than 100 self-developed innovative candidates in the pipeline and operates over 400 clinical trials throughout the world.
The approach of the company establishes a continuous development cycle which begins with the approval of drugs and proceeds to the initiation of clinical trials and the development of new drugs.
The organization has developed multiple world-class technology platforms which include proteolysis-targeting chimeras (PROTACs) and peptides, monoclonal antibodies, bispecific antibodies (BsAbs) and multi-specific antibodies and antibody drug conjugates (ADCs) and radioligand therapy and AI-driven drug discovery etc.
These platforms serve as a solid base which enables innovation and drives the company’s research and development activities.
Rewards & Recognitions
Hengrui has ranked on Pharma Exec's annual list of the top 50 global pharmaceutical companies for seven consecutive years. According to the list of the world's top 25 pipeline-scale pharmaceutical companies released by Citeline, an internationally renowned consulting organization, Hengrui has maintained its presence on the list for four consecutive years while it holds the second position worldwide for the number of its independently developed pipelines.
Promoting a Healthier Life for Humankind
Hengrui has chosen globalization as its primary strategic approach for achieving long-term business growth. Hengrui currently distributes its pharmaceutical products to more than 50 countries while the company plans to grow its international operations, especially in developing markets.
The company conducts research and development through its own efforts while partnering with external organizations to develop international ties which stem from its internal growth. Since 2023, Hengrui has completed 12 international business development deals for its new drugs which have a combined potential worth exceeding USD 27 billion and ownership stakes in specific partners.
The company has received U.S. FDA Fast Track Designation for four of its innovative drugs and Orphan Drug Designation for five additional medications which it has developed. Hengrui has successfully obtained around 20 registration approvals across the European Union, the United States and Japan for its injection products and oral formulations and inhalation anesthetics which will help more patients around the globe.
Hengrui will proceed with the mission of "promoting a healthier life for humankind through advancements in science" and adhere to its vision of "becoming a global biopharmaceutical group through innovation".
The organization plans to maintain its commitment to developing new treatments for various diseases while creating innovative medications that will serve patients throughout the world.
We use cookies to ensure you get the best experience on our website. Read more...
